Research Analysts Issue Forecasts for TCRX FY2025 Earnings

Key Points

• HC Wainwright has increased its FY2025 earnings per share estimate for TScan Therapeutics from ($1.18) to ($1.17), maintaining a "Buy" rating and a price target of $10.00.
• TScan Therapeutics reported a quarterly earnings per share of ($0.28), aligning with analysts' expectations, and achieved revenue of $3.08 million against estimates of $1.31 million.
• Institutional investors hold 82.83% of TScan Therapeutics' stock, indicating strong institutional interest in the company.

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Stock analysts at HC Wainwright boosted their FY2025 EPS estimates for shares of TScan Therapeutics in a report released on Tuesday, August 12th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($1.17) per share for the year, up from their previous estimate of ($1.18). HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for TScan Therapeutics' FY2026 earnings at ($1.16) EPS, FY2027 earnings at ($0.83) EPS, FY2028 earnings at ($0.47) EPS and FY2029 earnings at $0.04 EPS.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.28). TScan Therapeutics had a negative net margin of 1,964.88% and a negative return on equity of 63.33%. The business had revenue of $3.08 million for the quarter, compared to the consensus estimate of $1.31 million.

TCRX has been the subject of a number of other research reports. Wall Street Zen upgraded TScan Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, July 12th. Wedbush restated an "outperform" rating and set a $7.00 target price on shares of TScan Therapeutics in a research report on Tuesday, August 12th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, TScan Therapeutics has a consensus rating of "Buy" and a consensus price target of $7.80.

TScan Therapeutics Trading Down 6.1%

Shares of NASDAQ:TCRX traded down $0.11 during trading on Friday, hitting $1.68. 250,517 shares of the company's stock were exchanged, compared to its average volume of 256,112. The company has a current ratio of 7.06, a quick ratio of 7.06 and a debt-to-equity ratio of 0.18. The firm has a market cap of $95.07 million, a P/E ratio of -1.54 and a beta of 0.99. The firm has a 50-day moving average price of $1.68 and a two-hundred day moving average price of $1.65. TScan Therapeutics has a 1-year low of $1.02 and a 1-year high of $6.2250.

Institutional Investors Weigh In On TScan Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Lynx1 Capital Management LP boosted its stake in TScan Therapeutics by 2.5% in the 4th quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company's stock worth $16,286,000 after purchasing an additional 132,747 shares during the period. BVF Inc. IL lifted its holdings in shares of TScan Therapeutics by 6.9% in the second quarter. BVF Inc. IL now owns 5,226,074 shares of the company's stock valued at $7,578,000 after purchasing an additional 336,600 shares in the last quarter. Checkpoint Capital L.P. boosted its position in shares of TScan Therapeutics by 14.9% during the first quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company's stock worth $2,784,000 after buying an additional 261,663 shares during the period. Aberdeen Group plc grew its holdings in shares of TScan Therapeutics by 0.9% during the first quarter. Aberdeen Group plc now owns 891,448 shares of the company's stock worth $1,230,000 after buying an additional 7,744 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of TScan Therapeutics by 8.5% during the second quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company's stock worth $417,000 after buying an additional 22,642 shares in the last quarter. 82.83% of the stock is currently owned by institutional investors and hedge funds.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.